問卷二:針對國際醫(yī)療產(chǎn)品采購/進口企業(yè)的ESG影響因素調(diào)查

導(dǎo)語:Dear Sir/Madam, We are conducting a research study on how ESG (Environmental, Social, and Governance) reporting influences international trade in the healthcare industry. This questionnaire aims to understand the extent to which ESG factors influence your company's procurement and import decisions regarding medical products. This survey is solely for academic purposes, and all responses will be kept strictly confidential and anonymized. Thank you for your valuable time and support!
Part 1: Company and Respondent Profile
1. Your company's primary business belongs to which segment of the healthcare industry? (Single choice)
2. Does your company have procurement sources or import medical products from China? (Single choice)
3. The region where your company is headquartered: (Single choice)
4. What is your job function? (Single choice)
5. What is your work experience in the industry? (Single choice)
Part 2: ESG Perception and Integration (Q6-Q15, 10 questions)6. Does your company have a formal ESG or sustainability strategy? (Single choice)
7. How important is the ESG performance of a supplier when making procurement decisions for medical products? (Single choice, scale 1-5)
  • 1
  • 2
  • 3
  • 4
  • 5
 
8. What are the primary drivers for your company to consider ESG in procurement? (Multiple choice)
9. Which ESG aspects are currently included in your supplier assessment criteria? (Multiple choice)
10. Has your company set Scope 3 emissions reduction targets that include your supply chain? (Single choice)
11. Which frameworks do you primarily use to guide your ESG assessments? (Multiple choice)
12. How would you rate the level of commitment from your top management to ESG-driven procurement? (Single choice, scale 1-5)
  • 1
  • 2
  • 3
  • 4
  • 5
 
13. Does your company conduct on-site audits specifically for ESG compliance? (Single choice)
14. How does your company handle suppliers that fail to meet your ESG standards? (Single choice)
15. What is the biggest internal hurdle in implementing ESG procurement? (Single choice)
Part 3: The Impact of ESG on Sourcing Decisions (Please rate your agreement: 1=Strongly Disagree, 5=Strongly Agree) (Q16-Q45, 30 questions)
  • 1
  • 2
  • 3
  • 4
  • 5
Environmental (E) Factors:16. A supplier's carbon footprint and environmental certification are important factors in our selection process.
17. We prioritize suppliers who use sustainable materials and recyclable packaging for their products.
18. We are willing to pay a premium for medical products with a lower environmental impact.
19. Evidence of pollution or non-compliance with environmental regulations would be
20. Biodiversity impact is an emerging factor we consider in our supply chain.
21. We evaluate suppliers' water usage and wastewater management practices.
22. We encourage/require suppliers to have circular economy initiatives (e.g., device refurbishment).
23. The environmental footprint of logistics and transportation is part of our assessment.
Social (S) Factors:24. We conduct due diligence to ensure our suppliers uphold human rights and fair labor practices in their operations.
25. The ethical sourcing of materials (e.g., conflict minerals) is a concern for our company.
26. A supplier's commitment to employee health and safety is a significant consideration.
27. Incidents related to product safety or quality would severely damage our trust in a supplier.
28. Diversity, Equity, and Inclusion (DEI) within the supplier's workforce is evaluated.
29. Community engagement and positive social impact of the supplier's operations are valued.
30. Patient access and affordability of medicines/products are part of our social responsibility considerations.
31. Data privacy and security for connected health devices are critical social factors.
Governance (G) Factors:
32. Transparent business practices and strong anti-corruption policies are essential for us to engage with a supplier.
33. Data security and privacy practices are critically evaluated, especially for suppliers of digital health solutions.
34. Supply chain transparency and traceability are important for risk management.
35. We prefer suppliers that have diverse and independent governance structures.
36. Executive compensation linked to ESG performance is viewed positively.
37. Shareholder rights and engagement practices are noted.
38. Ethical guidelines for AI and algorithm transparency in health tech are a new governance priority.
39. Robust systems to prevent "greenwashing" are important for credibility.
Market & Sourcing Impact:40. A strong ESG profile can make a supplier from an emerging market (e.g., China) more attractive to us.
41. ESG issues have directly caused us to switch or disqualify a potential supplier in the past.
42. We provide training or guidelines to our existing suppliers to help them improve their ESG performance.
43. We believe robust ESG practices are indicative of a supplier's overall reliability and long-term viability.
44. Cost remains a more decisive factor than ESG performance in our final procurement decisions. (Reverse score)
45. Strong ESG performance is a key factor for strategic partnership and long-term contracts.
Part 4: Challenges and Perspectives on Specific Regions (Q46-Q50, 5 questions) 46. What are the biggest challenges in implementing ESG-based procurement? (Multiple choice)
47.How do you perceive the ESG performance of medical product suppliers from China compared to those from other regions? (Single choice)
48.What kind of ESG information or certification from a Chinese supplier would you find most credible? (Multiple choice)
49.Which upcoming ESG regulation (e.g., EU CSDDD) concerns you the most in terms of supply chain compliance? (Single choice)
50.Overall, do you believe the emphasis on ESG in procurement is? (Single choice)
51. In your view, which ESG factor (E, S, or G) is currently the most decisive in selecting a medical product supplier? Why?
52. Could you share an example where a supplier's ESG performance positively influenced your sourcing decision, or conversely, where a failure led to termination?
53. How do you balance the tension between cost competitiveness and ESG standards when sourcing from cost-sensitive regions?
54. What are your expectations for suppliers in improving their ESG disclosure and performance over the next 3-5 years?
55. Do you believe current global ESG standards adequately address the specific challenges of the healthcare industry (e.g., bioethics, single-use plastic waste)? Please elaborate.
56. What role should digitalization (e.g., blockchain, IoT) play in enhancing ESG transparency in the medical supply chain?
57. How does your company assess the "Social" component of ESG when dealing with suppliers from different cultural and regulatory backgrounds?
58. In your opinion, what is the single biggest obstacle for Chinese medical suppliers to improve their ESG image in your market?
59. How will evolving ESG regulations (e.g., EU's CSRD) reshape your future sourcing strategy and geographic preferences?
60. What advice would you give to a medical supplier who wishes to become a preferred partner for ESG-conscious companies like yours?
更多問卷 復(fù)制此問卷